Skip Navigation



Rheumatology Advance Access published online on May 18, 2005
Rheumatology, doi:10.1093/rheumatology/keh669
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/7/939    most recent
keh669v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Keat, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keat, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© British Society for Rheumatology 2005; all rights reserved
Received August 20, 2004
Accepted March 29, 2005

Guidelines

BSR guidelines for prescribing TNF-{alpha} blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology

A. Keat 1*, N. Barkham 2, A. Bhalla 3, K. Gaffney 4, H. Marzo-Ortega 2, S. Paul 5, F. Rogers 6, M. Somerville 4, R. Sturrock 7, P. Wordsworth 8, and on behalf of the BSR standards and audit working group

1 Northwick Park Hospital, Harrow, UK
2 Leeds General Infirmary, Leeds, UK
3 RNHRD, Bath, UK
4 Norfolk and Norwich Hospital, Norwich, UK
5 St Thomas' Hospital, London, UK
6 National Ankylosing Spondylitis Society, Mayfield, UK
7 University of Glasgow and Glasgow Royal Infirmary, Glasgow, UK
8 University of Oxford and Nuffield Orthopaedic Centre, Oxford, UK

* To whom correspondence should be addressed.
A. Keat, E-mail: andrew.keat{at}nwlh.nhs.uk



This article has no Abstract.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
L. C. Coates, L. S. Cawkwell, N. W. F. Ng, A. N. Bennett, D. J. Bryer, A. D. Fraser, P. Emery, and H. Marzo-Ortega
Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis
Rheumatology, June 1, 2008; 47(6): 897 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. C. Keat, K. Gaffney, A. K. Gilbert, C. Harris, and J. Leeder
Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis
Rheumatology, April 1, 2008; 47(4): 481 - 483.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. M. Ara, J. C. Packham, and K. L. Haywood
The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit
Rheumatology, January 1, 2008; 47(1): 68 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. F. Botteman, J. W. Hay, M. P. Luo, A. S. Curry, R. L. Wong, and B. A. van Hout
Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom
Rheumatology, August 1, 2007; 46(8): 1320 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. M. Ara, A. V. Reynolds, and P. Conway
The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK
Rheumatology, August 1, 2007; 46(8): 1338 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. N. Jois, K. Gaffney, and A. Keat
Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues
Rheumatology, June 1, 2007; 46(6): 899 - 901.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. Braun, N. McHugh, A. Singh, J. S. Wajdula, and R. Sato
Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly
Rheumatology, June 1, 2007; 46(6): 999 - 1004.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
N. Smith, K. Gadsby, S. Butt, and C. Deighton
The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis
Rheumatology, June 1, 2007; 46(6): 1044 - 1045.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
K. Gadsby and C. Deighton
Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis
Rheumatology, March 1, 2007; 46(3): 439 - 441.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. J. Kay, I. D. Griffiths, and for the BSR Biologics Register Management committe
UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register
Rheumatology, November 1, 2006; 45(11): 1376 - 1379.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Keat, R. Sturrock, M. Somerville, and S. Paul
BSR guidelines for TNF blockers in ankylosing spondylitis: reply
Rheumatology, September 1, 2006; 45(9): 1177 - 1178.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.